International Thyroid Congress

Dr. Paul Walfish on PD-1 Expression in Thyroid Cancer

October 24, 2015

Paul Walfish, MD, professor emeritus at the University of Toronto School of Medicine, senior consult Mount Sinai Hospital discusses programmed death ligand 1 (PD-1) expression in aggressive metastatic papillary thyroid cancer.

Japanese Clinical Trial Aims to Standardize Anaplastic Thyroid Carcinoma Treatment

October 24, 2015

A Japanese research team attempted to standardize therapy for anaplastic thyroid carcinoma by assessing the feasibility and efficacy of weekly paclitaxel administration.

Immunotherapy May Lead to Abnormal Thyroid Function in Patients With Cancer

October 23, 2015

A comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.

PD-L1 Strongly Correlates With Papillary Thyroid Cancer Aggressiveness

October 23, 2015

Investigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.

Dr. Michael Tuttle on Dosimetry Versus Empiric Dosing Radioactive Iodine Treatment

October 23, 2015

Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.

Next-Generation Sequencing Suggests BRAF With TERT Comutation Occurs in Advanced Well-differentiated Thyroid Cancer

October 23, 2015

Researchers have posited that well-differentiated thyroid cancers harbor distinct molecular pathological profiles that may be useful as prognostic indicators of future aggressiveness.

Sub-Centimeter Thyroid Nodule Size May Not Offer Good Prognostic Indicator for Biopsy

October 22, 2015

The rising overall risk of all sizes of malignant thyroid cancer has made clinicians question whether or not sub-centimeter thyroid nodules should also be biopsied.

Molecular Profiling of Medullary Thyroid Cancer Identifies Prognostic Markers for Vandetanib

October 22, 2015

While medullary thyroid cancer is not common as other thyroid cancers, it does have a poorer prognosis than these more common forms of metastatic thyroid cancer.

Dr. Delivanis on Pembrolizumab-Induced Thyroiditis

October 22, 2015

Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.

Anti-BRAF V600E Plus Antiangiogenesis May Possess Greater Activity Against Metastatic Papillary Thyroid Carcinoma

October 22, 2015

BRAF V600E is essential to the survival of many tumors and has been the focus of targeted therapeutics like a new BRAF V600E-selective inhibitor, which has been used for papillary thyroid carcinomas.